Masimo Corp Stock Price, News & Analysis

Masimo has announced findings from a study published in the Egyptian Journal of Anesthesia, showing that its SpHb technology provides clinically acceptable accuracy for hemoglobin measurement during elective cesarean sections with antepartum hemorrhage. The study demonstrated significant correlations between SpHb and invasive hemoglobin values at key measurement points. Continuous monitoring using SpHb may enhance transfusion practices and patient safety, with implications for quicker clinical decisions.

Masimo (NASDAQ: MASI) has expanded its HEOS platform, enabling seamless integration of health data from Masimo devices with over 4 million HEOS-enabled devices globally. This innovation provides users with continuous access to health metrics such as oxygen saturation and pulse rate and allows data sharing with clinicians. The upgrade will first be available on 20,000 HEOS Denon Home devices and Masimo Home Health Hubs in the U.S., with broader activation planned in 2023. Masimo aims to enhance healthcare delivery through a cloud-based IoT ecosystem that prioritizes secure health data management.

Masimo Corporation (NASDAQ: MASI) recently hosted its Investor Day, where the management team presented updates on strategic plans and growth opportunities. The company aims to leverage its robust capabilities in patient monitoring to enter new markets, including wearables and telemonitoring, with a total addressable market exceeding $150 billion. The acquisition of Sound United is set to enhance product development and marketing strategies across healthcare and consumer health. Masimo's commitment to innovation aims to improve health outcomes while driving revenue growth.

Masimo (NASDAQ: MASI) has announced the limited market release of Sepsis Index (Si™), an early warning solution for identifying potential sepsis in patients monitored with Masimo Patient SafetyNet™. This system integrates real-time physiological data to provide a sepsis risk score, allowing clinicians to detect and respond to patient deterioration more effectively. Sepsis affects approximately 1.7 million adults annually in the U.S. with significant mortality rates. The Sepsis Index aims to improve patient outcomes through timely interventions, although it is not FDA cleared.

Masimo (NASDAQ: MASI) has launched the full market release of its Hydration Index (Hi™), integrated within the Masimo W1™ watch. This advanced health-tracking wearable offers continuous pulse oximetry and hydration level monitoring, crucial for athletes and health-conscious individuals. The technology builds on Masimo's expertise in pulse oximetry, enabling users to assess hydration and physiological status in real-time. Notably, the product has not received FDA clearance for medical use in the U.S.

Masimo (NASDAQ: MASI) announced a controlled trial published in the Journal of the College of Physicians and Surgeons Pakistan, showing the benefits of its SpHb® hemoglobin monitoring technology in major surgeries. The study found that patients monitored with SpHb had significantly lower postoperative red blood cell transfusion rates (median 0 IUs for SpHb group versus 2 IUs for control; p=0.020) and higher hemoglobin levels in ICU (8.41 g/dL vs. 7.75 g/dL; p=0.033). Researchers emphasized that SpHb can enhance patient blood management, potentially reducing mortality and morbidity.

Masimo (NASDAQ: MASI) will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:30 a.m. ET. A live webcast of the presentation will be accessible on Masimo's website, with a replay available afterward. Masimo is a leader in medical technology, focusing on innovative monitoring solutions that enhance patient outcomes and lower care costs. Their SET pulse oximetry technology, utilized globally, has proven effective in critical applications for neonatal care and surgical monitoring.

The United States District Court for the Central District of California has ruled in favor of Masimo (NASDAQ: MASI), determining that former engineer Marcelo Lamego misappropriated trade secrets related to Masimo’s pulse oximetry technology. The court ordered Lamego to abandon patent applications and return confidential information. Furthermore, the sale of Lamego's True Wearables pulse oximeter is permanently enjoined due to the misuse of Masimo's trade secrets. Masimo has another pending lawsuit against Apple scheduled for trial in March 2023, alleging further misappropriation of trade secrets.

Masimo (NASDAQ: MASI) will participate in the Stifel 2022 Healthcare Conference on November 15, 2022, at 1:50 p.m. Eastern Time. A live webcast will be available on their website, with a replay following the presentation. Masimo specializes in innovative medical monitoring technologies, including noninvasive pulse oximetry and continuous monitoring tools, aiming to improve patient outcomes while reducing healthcare costs. Their products are utilized in over 100 million patients globally, establishing their presence in leading hospitals worldwide.